JAZZ PHARMACEUT. DL-,0001
JAZZ PHARMACEUT. DL-,0001/ IE00B4Q5ZN47 /
J7Z
2024-05-03 8:08:17 AM
|
Chg.
+0.05
|
Volume |
Bid1:49:06 PM |
Ask1:49:06 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
101.65EUR
|
+0.05%
|
0 Turnover: 0.00 |
101.60Bid Size: 50 |
103.05Ask Size: 49 |
6.42 bill.EUR |
- |
- |
Business description
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.
Management board & Supervisory board
CEO |
Bruce C. Cozadd |
Management board |
Pater Gray, Jeninfer Cook, Patrcik G. Enright, Heather Ann McSharry, Seamus Mulligan |
Supervisory board |
- |